Statistics for Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
Total visits
views | |
---|---|
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial | 296 |
Total visits per month
views | |
---|---|
September 2024 | 0 |
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
File Visits
views | |
---|---|
Gane_2016_efficacy.pdf | 305 |
java.util.UUID:18bb4e44-8631-45f9-bb09-8995be59667a | 46 |
java.util.UUID:15acb955-eb1d-4c56-bd33-543a967c7445 | 15 |
java.util.UUID:3ce470ed-a303-4ecb-b960-d5f287ebb205 | 10 |
Top country views
views | |
---|---|
United States | 197 |
Germany | 24 |
China | 11 |
Ukraine | 8 |
United Kingdom | 6 |
Russia | 5 |
Sweden | 5 |
Canada | 2 |
Australia | 1 |
Egypt | 1 |
France | 1 |
Greece | 1 |
Lebanon | 1 |
Lithuania | 1 |
Malaysia | 1 |
Netherlands | 1 |
Philippines | 1 |
Pakistan | 1 |
Poland | 1 |
Portugal | 1 |
Taiwan | 1 |
Top city views
views | |
---|---|
Wilmington | 52 |
Fairfield | 38 |
Kiez | 19 |
White Plains | 12 |
Ann Arbor | 11 |
Cambridge | 11 |
Houston | 9 |
Jacksonville | 7 |
Kiev | 6 |
Gunzenhausen | 5 |
Stockholm | 4 |
Washington | 4 |
Beijing | 3 |
Saint Petersburg | 3 |
Brooklyn | 2 |
Chengdu | 2 |
Moscow | 2 |
Norwalk | 2 |
San Francisco | 2 |
Shanghai | 2 |
Alexandria | 1 |
Athens | 1 |
Augusta | 1 |
Beirut | 1 |
Cairo | 1 |
Carbondale | 1 |
Chongqing | 1 |
Coimbra | 1 |
Dniepropetrovsk | 1 |
Fort Washington | 1 |
Henryk | 1 |
Kalmar | 1 |
Karachi | 1 |
Lake Mary | 1 |
Lexington | 1 |
London | 1 |
Makati | 1 |
Montreal | 1 |
Mount Pleasant | 1 |
New York | 1 |
Nijmegen | 1 |
Paris | 1 |
Philadelphia | 1 |
Portland | 1 |
Radcliffe | 1 |
Ridgefield | 1 |
Rockville | 1 |
Scottsdale | 1 |
Seremban | 1 |
Shenzhen | 1 |
Sydney | 1 |
Taipei | 1 |
Toledo | 1 |
Toronto | 1 |
Vilnius | 1 |